author-photo

Oluwakayode Adejoro

Merck & Co.

3

Papers

4

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.

2020 Current Medical Research and Opinion
Show All
- Source
- Cite
- Save
Citations (3)